Related Experiment Videos
Neoadjuvant therapy for locally invasive bladder cancer
Urologia Internationalis
|January 1, 1989
Summary
Neoadjuvant PVB and CAP chemotherapy show promise for locally invasive bladder cancer. Both regimens demonstrated effectiveness in response rates and downstaging, suggesting their utility in patient management.
Area of Science:
- Oncology
- Urology
- Clinical Trials
Background:
- Locally invasive bladder cancer requires effective neoadjuvant treatment strategies.
- Evaluating chemotherapy regimens prior to definitive treatment can improve outcomes.
Purpose of the Study:
- To assess the efficacy of neoadjuvant PVB (cisplatin, vinblastine, bleomycin) and CAP (cisplatin, doxorubicin, cyclophosphamide) regimens in locally invasive bladder cancer.
- To compare response rates, downstaging, and survival outcomes between the two neoadjuvant therapies.
Main Methods:
- A retrospective nonrandomized study of neoadjuvant PVB therapy (n=25).
- A randomized controlled study of neoadjuvant CAP therapy (n=31).
- Data collected on complete response (CR), partial response (PR), downstaging, and survival rates.
Main Results:
- PVB group: 71.4% CR+PR rate and 71.4% downstaging.
- CAP group: 50.0% CR+PR rate and 88.9% downstaging.
- 2-year survival: PVB 78.6%, CAP 100%; 5-year survival (PVB): 60.6%. No statistical significance in survival rates.
Conclusions:
- Neoadjuvant PVB and CAP regimens are potentially useful in managing invasive bladder cancer.
- Both regimens show activity in terms of tumor response and downstaging.
- Further investigation may be warranted to optimize treatment selection and improve survival.